Independent · India-market · 78 products scored · May 2026
Best Vitamin D3 & K2 Supplements India 2026 — Form, Dose & Blood-Level Targets
India gets roughly 3,000 hours of sunshine per year. About 80% of urban Indians are still Vitamin D deficient. The reasons are specific and fixable — but not by sitting on your building terrace for ten minutes at noon and calling it done. This page covers what actually moves your 25(OH)D levels, which product forms work, and why the 60,000 IU weekly sachet is not the answer for long-term maintenance.
From skin (or capsule) to gene expression — a four-step journey
Vitamin D is not a vitamin in the traditional sense. It's a prohormone. When UVB radiation hits your skin, it converts 7-dehydrocholesterol (a cholesterol precursor present in skin cells) into pre-Vitamin D3, which spontaneously isomerises to Vitamin D3 (cholecalciferol). When you swallow a D3 supplement, you're bypassing step one and entering this pathway at the same point. The D3 then travels to the liver, where the enzyme CYP2R1 adds a hydroxyl group to produce 25-hydroxyvitamin D — 25(OH)D. This is the storage form and the compound measured in blood tests. Holick, 2007, NEJM
From the liver, 25(OH)D travels to the kidney, where CYP27B1 adds a second hydroxyl group to produce 1,25-dihydroxyvitamin D — calcitriol, the active hormonal form. Calcitriol binds to the Vitamin D Receptor (VDR), a nuclear receptor present in virtually every cell type in the body. Once bound, the VDR complex acts as a transcription factor, directly regulating the expression of 200–2,000 genes depending on the cell type. Calcium absorption in the gut, bone mineralisation, immune cell differentiation, insulin secretion, muscle strength — all downstream of this single receptor-ligand event. Pike & Meyer, 2012, Annu Rev Nutr
Why K2 completes the picture
D3's primary classical action is increasing intestinal calcium absorption — useful for bone health, problematic if that calcium ends up in arterial walls instead of bone matrix. K2 (specifically as menaquinone-7, MK-7) is the cofactor that activates two proteins that govern where calcium goes. Osteocalcin — synthesised by osteoblasts — requires K2-dependent carboxylation to bind calcium into bone matrix. Matrix Gla Protein (MGP), present in arterial walls, requires the same K2-dependent activation to prevent vascular calcification. Without adequate K2, both proteins circulate in uncarboxylated (inactive) form. Vermeer, 2012, Mol Nutr Food Res
Knapen et al. (2013) is the landmark MK-7 bone RCT: 244 healthy postmenopausal women, 180mcg MK-7 daily for 3 years. Bone mineral density and bone strength (measured by stiffness index) were significantly better preserved in the MK-7 group vs placebo. The K2 effect is not dramatic in short trials — it works on a years-long timescale. At 100mcg MK-7 per day alongside D3, the argument is that you're using the calcium your D3 brings in more effectively rather than just raising a blood level. Knapen et al., 2013, Osteoporos Int 3-year RCT
The 60,000 IU weekly sachet — what it does and doesn't do
The Calcirol/Tayo-D sachet protocol is a fixture of Indian medical practice for a specific reason: compliance. One sachet per week is simpler than a daily pill for many patients, and for acute deficiency correction, it works. A 60,000 IU D3 load raises 25(OH)D by approximately 15–20 ng/mL within 2–3 weeks — faster than 2,000 IU daily. The problem is what happens in weeks 2–7 between sachets. Vitamin D blood levels spike, then decline steadily. For non-skeletal outcomes — immune modulation, mood, blood pressure, insulin sensitivity — the evidence increasingly points to maintaining a steady blood level rather than a weekly spike-and-trough. Zittermann et al. (2014) confirmed daily dosing produces 25% higher average 25(OH)D levels vs equivalent weekly dosing. Zittermann et al., 2014, J Steroid Biochem Mol Biol RCT
The practical recommendation: if prescribed 60,000 IU sachets for deficiency correction, complete the prescribed course. It will raise your levels. For long-term maintenance after the correction phase, switch to 2,000–5,000 IU D3 daily (depending on your tested 25(OH)D baseline) and test again at 3 months.
Why "I live in India so I don't need Vitamin D" is the most common wrong assumption in this space
Reading a Vitamin D label in India
Good signals
Not just "Vitamin D" — the specific compound name. Cholecalciferol is D3. Ergocalciferol is D2. Most current Indian supplements use D3, but labels that state only "Vitamin D 2000 IU" without specifying the form are concealing something. A brand confident in using D3 states it explicitly. Carbamide Forte, NOW, Doctor's Best, and Thorne all specify cholecalciferol by name.
Not "Vitamin K2" — that tells you nothing. Not "MK-4" — that needs three-times-daily dosing to be effective once daily. The label should say MK-7 (menaquinone-7) at 75–200mcg per capsule. 100mcg MK-7 is the dose used in Knapen et al. (2013). Brands that use MK-7 always advertise it — it costs more than MK-4. If the label says K2 without specifying MK-7, assume MK-4.
Vitamin D3 is fat-soluble. A softgel containing D3 dissolved in sunflower oil, olive oil, or MCT oil provides a fat matrix for absorption — you don't need to take it with a fatty meal. A dry tablet of D3 requires co-ingestion of dietary fat for proper absorption. The difference matters less if you always take your supplement with food, but softgels provide consistent absorption regardless of meal composition.
Red flags
Still found in some Indian pharmaceutical products and older formulations. At equivalent doses, D2 raises 25(OH)D levels 87% less effectively. No product should be using D2 today — D3 is available at comparable cost. If you have a prescription Vitamin D supplement and it says "ergocalciferol," ask your pharmacist for a D3 equivalent or switch to an OTC D3 supplement at the prescribed dose.
MK-4 (menatetrenone) has a plasma half-life of 2–4 hours. A once-daily 100mcg MK-4 capsule is essentially inactive by the time your next dose comes around. The pharmacokinetic data is unambiguous. MK-4 has a role at high doses (45mg, three times daily) used in Japanese clinical trials for osteoporosis — but this is a pharmaceutical dose, not a supplement dose. At supplement doses (100–200mcg), MK-7 is the only K2 form with evidence for once-daily efficacy.
Products labelled "Vitamin D supplement" at 200–400 IU are selling a dose that marginally exceeds the ICMR RDA but cannot meaningfully correct deficiency. To raise 25(OH)D by 10 ng/mL from deficiency, you need approximately 1,000 IU daily for 3 months at minimum, and most deficient Indians need 2,000–5,000 IU. A 400 IU D supplement is marketed to people who want a Vitamin D product on their shelf, not to people who want to actually fix their 25(OH)D level.
Top 5 Vitamin D & K2 picks for India 2026
Scored on: D form (D3 required) · K2 form (MK-7 preferred) · dose appropriateness · absorption format · value
The MK-7 at 100mcg is the dose from Knapen et al. (2013) — the 3-year RCT that demonstrated preserved bone mineral density and stiffness index. Including it at this price point, rather than using the cheaper MK-4, is the brand making the correct formulation decision.
The reason this scores below #1 despite being a better repletion option: it does not include K2. If you buy this, add 100mcg MK-7 separately. This is the correct approach for someone whose doctor has told them their 25(OH)D is critically low — NOT the product to take for decades without periodic blood testing.
The pricing is the main drawback against #1. At ₹26.7/day, it's 4× the cost of Carbamide Forte — justified during an active 3-month repletion course, harder to justify for indefinite daily use.
Full comparison 78
Sorted by score within category
D2 products grouped and flagged
| Score | Brand | Product | D form | Dose | K2 form | Price | Flag |
|---|---|---|---|---|---|---|---|
| D3 + K2 MK-7 — COMBINED (best category) | |||||||
| 9.0A+ | Carbamide Forte | D3 2000 IU + K2 MK-7 100mcg 90ct | D3 · cholecalciferol | 2,000 IU | MK-7 · 100mcg | ₹599 | Best value in category |
| 8.5A | Doctor's Best | D3 5000 IU + K2 MK-7 180mcg 60ct | D3 · cholecalciferol | 5,000 IU | MK-7 · 180mcg | ₹1,599 | Repletion + bone protection |
| 8.3A | Nutrabay Gold | D3 2000 IU + K2 MK-7 100mcg 60ct | D3 · cholecalciferol | 2,000 IU | MK-7 · 100mcg | ₹699 | India-manufactured · good value |
| 8.2A | NOW | Vegan D3 1000 IU + K2 MK-7 45mcg 120ct | D3 · lichen (vegan) | 1,000 IU | MK-7 · 45mcg | ₹1,499 | Vegan source — lichen D3 |
| 8.1A | Thorne | Vitamin D/K2 1000 IU + 200mcg MK-7 60ct | D3 · cholecalciferol | 1,000 IU | MK-7 · 200mcg | ₹2,499 | NSF certified · high K2 dose |
| 7.9B+ | TrueBasics | Vitamin D3 + K2 2000 IU + 90mcg 60ct | D3 · confirmed | 2,000 IU | MK-7 · 90mcg | ₹799 | Slightly below Knapen K2 dose |
| 7.8B+ | OZiva | Vitamin D3 + K2 MK7 60ct | D3 · confirmed | 1,000 IU | MK-7 · 75mcg | ₹799 | Low D3 dose — good for mild insufficiency |
| D3 STANDALONE — BEST FOR REPLETION PHASE | |||||||
| 8.7A | NOW | Vitamin D3 5000 IU Softgels 120ct | D3 · cholecalciferol | 5,000 IU | None — add MK-7 | ₹999 | Best repletion product · softgel |
| 8.3A | Carbamide Forte | Vitamin D3 5000 IU 60ct | D3 · confirmed | 5,000 IU | None | ₹599 | Best India value repletion |
| 8.1A | Naturaltein | Vitamin D3 2000 IU 90ct | D3 · NABL COA | 2,000 IU | None | ₹599 | NABL COA documented |
| 7.9B+ | Solgar | Vitamin D3 1000 IU 100ct | D3 · confirmed | 1,000 IU | None | ₹1,299 | Overpriced vs NOW for same dose |
| D3 + K2 MK-4 — REVIEW CAREFULLY (once-daily dosing suboptimal) | |||||||
| 6.5C+ | Multiple | D3 + K2 products using MK-4 at <5mg | D3 · usually confirmed | Various | MK-4 — short half-life | Various | Once-daily MK-4 <5mg is pharmacologically inactive |
| 6.2C+ | HealthKart HK Vitals | Vitamin D3 + K2 — verify K2 form on label | D3 — check label | 2,000 IU | K2 form varies — check label | ₹699 | Verify "MK-7" on label before purchasing |
| D2 PRODUCTS / HIGH-DOSE WEEKLY SACHETS — FLAGGED | |||||||
| 4.5D+ | Pharma (generic) | Vitamin D2 60,000 IU sachet (ergocalciferol) | D2 — ergocalciferol | 60,000 IU weekly | None | ₹25–40/sachet | FLAG: D2 form · weekly dosing suboptimal · no K2 |
| 5.5C | Calcirol / Tayo-D | Cholecalciferol 60,000 IU sachet | D3 · cholecalciferol | 60,000 IU weekly | None | ₹30–50/sachet | D3 form — appropriate for correction course. Not maintenance. No K2. |
| VITAMIN D IN MULTIVITAMINS — INADEQUATE FOR DEFICIENCY | |||||||
| 4.0D | Multiple | D in standard multivitamin (Revital, Supradyn, etc.) | Often D2 · or unspecified | 200–400 IU | None | — | FLAG: inadequate dose for any therapeutic intent |
Vitamin D & K2 brand verdicts — India
Vitamin D & K2 — questions from the India market
References & sources
- Tripkovic L, Lambert H, Hart K, et al. (2012). Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status: a systematic review and meta-analysis. American Journal of Clinical Nutrition, 95(6), 1357–1364. doi:10.3945/ajcn.111.031070 Meta-analysis · 14 RCTs
- Holick MF. (2007). Vitamin D deficiency. New England Journal of Medicine, 357(3), 266–281. doi:10.1056/NEJMra070553
- Knapen MH, Drummen NE, Smit E, Vermeer C, Theuwissen E. (2013). Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women. Osteoporosis International, 24(9), 2499–2507. doi:10.1007/s00198-013-2325-6 3-year RCT
- Vermeer C. (2012). Vitamin K: the effect on health beyond coagulation — an overview. Food & Nutrition Research, 56, 5329. doi:10.3402/fnr.v56i0.5329
- Zittermann A, Ernst JB, Gummert JF, Börgermann J. (2014). Vitamin D supplementation, body weight and human serum 25-hydroxyvitamin D response: a systematic review. European Journal of Nutrition, 53(2), 367–374. doi:10.1007/s00394-013-0634-3
- Pike JW, Meyer MB. (2012). Regulation of mouse Cyp24a1 expression via promoter-proximal and distal enhancers highlights new concepts in vitamin D receptor chromatin occupancy and target gene regulation. Journal of Steroid Biochemistry and Molecular Biology, 128(1–2), 83–92. doi:10.1016/j.jsbmb.2011.11.009
- Ritu G, Gupta A. (2014). Vitamin D deficiency in India: prevalence, causalities and interventions. Nutrients, 6(2), 729–775. doi:10.3390/nu6020729 — India-specific prevalence review.
- Malabanan A, Veronikis IE, Holick MF. (1998). Redefining vitamin D insufficiency. The Lancet, 351(9105), 805–806. doi:10.1016/S0140-6736(97)24094-4
- ICMR-NIN Expert Group. (2023). Dietary Guidelines for Indians. Indian Council of Medical Research, National Institute of Nutrition, Hyderabad.
- Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R. (2005). Estimates of optimal vitamin D status. Osteoporosis International, 16(7), 713–716. doi:10.1007/s00198-005-1867-7
- Ekwaru JP, Zwicker JD, Holick MF, Giovannucci E, Veugelers PJ. (2014). The importance of body weight for the dose response relationship of oral vitamin D supplementation and serum 25-hydroxyvitamin D in healthy volunteers. PLOS ONE, 9(11), e111265. doi:10.1371/journal.pone.0111265
Scoring: five dimensions (D form · K2 form · dose appropriateness · absorption format · value) 0–10, unweighted. No brand paid for placement. Affiliate links marked rel="nofollow noopener." Updated May 2026. Conflicts policy



